Benzinga · Feb 24, 2026
HC Wainwright & Co. Maintains Buy on Balchem, Maintains $190 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:BCPC) with a Buy and maintains $190 price target.

NASDAQ · BCPC
Basic Materials · Chemicals - Specialty
$181.28
Up+$1.65 (+0.92%)
Updated Aug 22, 2026, 4:21 AM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
BCPC closed at $181.28 after 21 trading sessions, up 11.34% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $181.73 | $181.815 | $178.67 | $181.28 | 137.89K |
| Aug 20, 2026 | $178.12 | $182.00 | $178.12 | $179.63 | 139.61K |
| Aug 19, 2026 | $178.52 | $181.765 | $178.24 | $180.19 | 131.06K |
| Aug 18, 2026 | $179.65 | $179.73 | $176.725 | $177.00 | 169.67K |
| Aug 17, 2026 | $177.24 | $179.265 | $176.54 | $178.38 | 108.62K |
| Aug 14, 2026 | $177.36 | $178.56 | $174.55 | $178.51 | 89.14K |
| Aug 13, 2026 | $182.065 | $182.065 | $176.34 | $177.14 | 164.94K |
| Aug 12, 2026 | $179.11 | $181.21 | $177.9275 | $179.76 | 137.91K |
| Aug 11, 2026 | $178.18 | $179.9325 | $176.51 | $179.01 | 119.14K |
| Aug 10, 2026 | $178.29 | $179.93 | $176.645 | $177.19 | 124.61K |
| Aug 7, 2026 | $179.37 | $180.48 | $178.45 | $179.43 | 175.61K |
| Aug 6, 2026 | $180.00 | $181.48 | $177.17 | $180.42 | 186.83K |
| Aug 5, 2026 | $174.78 | $178.89 | $173.46 | $178.79 | 267.46K |
| Aug 4, 2026 | $172.26 | $178.62 | $169.84 | $174.78 | 269.66K |
| Aug 3, 2026 | $170.75 | $177.05 | $170.28 | $173.57 | 262K |
| Jul 31, 2026 | $163.19 | $167.79 | $160.455 | $167.555 | 346.16K |
| Jul 30, 2026 | $163.32 | $164.16 | $160.89 | $162.73 | 271.85K |
| Jul 29, 2026 | $164.88 | $165.4175 | $163.45 | $163.71 | 157.7K |
| Jul 28, 2026 | $167.19 | $169.57 | $165.68 | $165.79 | 317.89K |
| Jul 27, 2026 | $163.66 | $165.4299 | $162.65 | $164.79 | 138.91K |
| Jul 24, 2026 | $161.58 | $163.72 | $161.45 | $162.81 | 129.73K |
The latest Smart Investors Daily articles mentioning BCPC.
BCPC research
Company profile and research snapshot.
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| May 4, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 24, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 5, 2025 | Rothschild & Co | Neutral | — |
| Oct 22, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Feb 24, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:BCPC) with a Buy and maintains $190 price target.
SeekingAlpha · Feb 20, 2026
ChartMill · Feb 20, 2026
Balchem Corp. (BCPC) reports record 2025 results, surpassing $1B in revenue. Q4 earnings met analyst expectations with steady growth across all segments.
SeekingAlpha · Feb 20, 2026
2026-02-20. The following slide deck was published by Balchem Corporation in conjunction with their 2025 Q4 earnings call.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning BCPC.